News

Antisense compound may provide new Alzheimer's treatment

A new antisense compound developed by Saint Louis University scientists restored learning, memory and other behaviors in mice genetically engineered...

Read more

Silencing the Huntingtin gene using ASO drugs reaches further, lasts longer and is safe. Human trial soon?

Drugs called anti-sense oligonucleotides, or ASOs, are one way of silencing the gene that causes Huntington’s disease. A new publication in...

Read more

El capital riesgo entra en la biotech granadina nLife

La sociedad impulsada por el Colegio de Médicos de Barcelona se suma al accionariado de la firma, participada mayoritariamente por...

Read more
Cabecera
 
Huntington - Duchene Muscular Distrophy
Parkinson – Alzheimer
Neuroinflammation - Obesity Control
Major Depressive Disorder

Neuronal-focused Therapies
for a Healthy Life

nLife at Biospain 2014

nLife Therapeutics

  • nLife Therapeutics is a biopharmaceutical company leading the discovery and development of neuronal specific oligonucleotides (nOligos)  as therapeutic agents for CNS disorders.
  • nLife Therapeutics provides a unique oligonucleotide delivery platform with strong IP protection targeting several neurodegenerative conditions
  • Lead Candidate (NLF-PD-1233) is a First in Class Disease modifying oligonucleotide treatment for Parkinson Disease
  • Programs targeting: Huntington, Alzheimer Disease, DucheneDisease, Neuro-inflammation, MDD and Obesity are also underway
 
Pipeline
Platform
 
Ministerio de Ciencia e Innovación: MICINN
Ministerio de Industria y Competitividad: MINECO
Centro para el Desarrollo Tecnológico e Industiral: CDTI
Unión Europea con el emblema de FEDER
Xunta de Galicia
Michael J. Fox Foundation